Business

Knome appoints Martin Tolar as chief executive

Knome Inc., a Cambridge life sciences company specializing in human genome interpretation, today announced that it has appointed Martin Tolar, M.D., as its chief executive.

Knome supports researchers with the informatics and software tools used to investigate the genetic basis of human disease and drug response.

Advertisement

Before joining Knome, Tolar was chief executive of Normoxys Inc., where he helped build a management team, secure venture financings, and advance the company’s novel cancer therapeutics from a research project into clinical development, Knome said in a press release.

Jorge Conde, Knome’s founding CEO, will become chief strategy officer and continue to serve on its board of directors, Knome said; in his new role, he will lead the development of Knome’s genome interpretation software and services.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.